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Abstract 
A 75-year-old female, who had an abnormal
stomach  x-ray  finding,  was  admitted  to  the
hospital for further examination and therapy.
Upper  GI  endoscopy  showed  reddish  and
swollen folds on the greater curvature of the
gastric body and a biopsy was of this lesion
revealed malignant lymphoma (small cell type
or mucosa-associated lymphoid tissue (MALT)
lymphoma suspected). The patient was infect-
ed with Helicobacter pylori (H. pylori), howev-
er, in response to the patient’s wishes, a total
gastrectomy,  omentectomy  and  splenectomy
were performed and the histological diagnosis
was gastric MALT lymphoma. Two courses of
CHOP therapy (cyclophosphamide (CPM) 750
mg/m2/day,  day  1,  adriamycin  (ADM)  50
mg/m2/day, day 1, vincristine sulfate (VCR) 1.4
mg/m2/day, day 1, prednisolone 100 mg/body,
day  1-5)  were  administered  as  adjuvant
chemotherapy.  A  colonoscopic  examination
performed  about  4.5  yr  after  the  operation
revealed  rectal  submucosal  tumors  and  the
biopsied specimens were diagnosed as malig-
nant  lymphoma.  A  transanal  focal  resection
was performed and the histological diagnosis
was metachronous and ectopic development of
MALT lymphoma. The histological finding was
similar to the gastric lesion. About 4 and 7 yr
after the first development of rectal MALT lym-
phoma, MALT lymphomas developed repeated-
ly  in  the  rectal  lesion,  however,  these  were
resected  repeatedly  and  no  developmenthas
occurred during the past two years. This report
presents a very rare case of metachronous and
ectopic MALT lymphoma development in the
gastric and rectal lesions.
Introduction
Mucosa-associated lymphoid tissue (MALT)
lymphoma is a lymphoma derived from B-cells
originating  from  the  marginal  zone  of  the
MALT in an extra-nodal organ in the presence
of chronic inflammations in the gastrointesti-
nal  tract,  thyroid  gland,  salivary  gland,  lung
and so on.1,2 Many cases of MALT lymphoma of
the  stomach  have  been  reported  to  date  in
association  with  an  Helicobacter  pylori (H.
pylori) infection, however, the development of
MALT lymphoma in the colon and rectum with-
out the apparent etiology such as an H. pylori
infection is comparably rare. Anecdotal reports
in which MALT lymphomas develop metachro-
nously in the same or different organs have
been reported to date.3-9 In the present case, a
focal resection was performed for MALT lym-
phoma developed metachronously and ectopi-
cally in the rectum 3 years after a total gastrec-
tomy for gastric MALT lymphoma followed by 2
courses of adjuvant chemotherapy. MALT lym-
phomas  developed  repeatedly  in  the  rectal
lesion,  however,  these  were  focally  resected
repeatedly  and  no  recurrence  has  occurred
over the past two years. This report presents a
very  rare  case  of  successfully  treated  MALT
lymphomas  that  developed  metachronously
and ectopically in gastric and rectal lesions.
Case Report
A 75-year-old woman showed an abnormali-
ty in the findings of barium X-ray screening for
gastric cancer and was transferred to our hos-
pital  (Medical  Hospital,  The  Nippon  Dental
University School of life Dentistry at Niigata)
for  further  examination  and  therapy  in
October  1995.  Upper  GI  endoscopy  revealed
swollen giant folds of the body (Figure 1A, 1B).
A biopsy was performed and malignant lym-
phoma  (small  cell  type  or  MALT  lymphoma)
was suspected. The background mucosa of the
stomach was positive for an H. pylori infection
in  a  retrospective  pathological  examination.
We did not perform any chromosomic study at
that  time.  Very  recently,  we  performed  the
FISH  assay  to  evaluate  the  translocation  of
t(11;18)  in  formalin  fixed  tissues  of  gastric
and colonic tumors, however, we could not per-
form any proper examination on this translo-
cation because the tumor tissues with forma-
lin fixation were in bad condition. A computed
tomography (CT) scan of the chest, abdomen
and  pelvic  lesion  demonstrated  no  swollen
lymph  nodes.  Although  there  were  several
options for treatment, the patient and her fam-
ily requested that the lesion be treated surgi-
cally.  A  total  gastrectomy,  omentectomy  and
splenectomy (D2 resection of regional lymph
nodes and Roux-en-Y gastrojejunostomy) were
thus performed in November 1995 (Figure 2 A,
B). The histopathological diagnosis was MALT
lymphoma (Figure 3 A,B) with a slight inva-
sion into the spleen. Lymphoepithelial lesion
(LEL),  positive  immunoreactivity  for  CD20
(L26) and CD79a, and negative immunoreac-
tivity for cyclin D1 and CD5 were observed (fig-
ure not shown). A Positive IgG-rearrangement
and monoclonal proliferation were confirmed
(figure not shown). The depth of greatest inva-
sion of the tumor was the muscularis propria.
No  metastatic  lymph  nodes  and  no  vestigial
remnant of the tumor were seen. Therefore,
the patient was diagnosed as stageⅡE by Ann
Arbor classification,10 as stageⅡE1 by Lugano
International classification11and as stageⅡ1 by
Blackledge Staging System.12 Two courses of
CHOP therapy (cyclophosphamide (CPM) 750
mg/m2/day,  day  1,  adriamycin  (ADM)  50
mg/m2/day, day 1, vincristine sulfate (VCR) 1.4
mg/m2/day, day 1, prednisolone 100 mg/body,
day  1-5)  were  administered  as  an  adjuvant
chemotherapy,  beginningDecember  11,  1995.
Afterward, the patient was followed as an out-
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patient.  A colonoscopic examination in May,
1999  showed  two  rectal  submucosal  tumors
(SMT), 2 cm or less in diameter (Figure 4 A,B).
A biopsy was performed and malignant lym-
phoma was suspected. A trans-anal focal resec-
tion of the tumor was performed in May, 1999.
The  histopathological  diagnosis  was  MALT
lymphoma  which  was  similar  to  the  gastric
lesion  which  had  been  resected  previously
(Figure 3 C,D). Lymphoepithelial lesion (LEL),
positive immunoreactivity for CD20 (L26) and
CD79a, and negative one for cyclin D1 and CD5
were  observed  (figure  not  shown).
Colonoscopy in February, 2003 showed a rectal
SMT (figure not shown) and the biopsy speci-
mens were diagnosed as lymphoid hyperplasia.
Trans-anal  focal  resection  of  the  tumor  was
performed in March, 2003. The histopathologi-
cal diagnosis also suggested lymphoid hyper-
plasia but could not be diagnosed as an appar-
ent  lymphoma.  Afterward,  colonoscopy  per-
formed in May, 2006 again revealed SMT-like
lesions (figure not shown). A biopsy was per-
formed  and  the  pathological  diagnosis  was
malignant  lymphoma  as  with  the  previously
resected tumors. A trans-anal focal resection
was again performed in June, 2006. The patho-
logical diagnosis was MALT lymphoma, which
strongly correlated with the pathological find-
ings of the tumor resected in May, 1999 and in
March, 2003, however, the malignant cells of
the tumor resected in June, 2006 were charac-
terized by well differentiated plasma cells (fig-
ure not shown). The patient is currently being
followed as an outpatient without additional
adjuvant chemotherapy, however, the patient
shows  no  sign  of  recurrence  of  MALT  lym-
phoma  and  her  serum  IL2-recepter  levels
remain within the normal limits.
Discussion
MALT lymphoma is a low grade malignant B-
cell  lymphoma  that  develops  from  mucosa-
associated lymphoid tissue (MALT). The con-
cept of MALT lymphoma was first introduced by
Isaacson et al.13 The pathological features of
MALT lymphoma are as follows: i) lymphoma
cells with faint, bright and abundant cell body
(clear  cells),  and  mildly  pinched-off  nuclei
(Centrocyte-like  cells:  CCLCs);  ii)  a  diffuse
proliferation in the marginal zone of monocyt-
Case Report
Figure 1. (A) Upper gastrointestinal endo-
scopic  findings  on  31  October  1994
showed swollen and reddish folds with ero-
sions.  (B)  Upper  gastrointestinal  endo-
scopic  findings  on  31  October  1994
stained with indigotindisulfo nate sodium
(indigo carmine).
Figure  2.  (A)  Gross  appearance  of  the
entire resected stomach, greater omentum
and  spleen.  (B)  Gross  appearance  of  the
resected gastric lesion of MALT lymphoma.
Swollen  folds,  so-called  giant  folds with
erosions were observed on the greater cur-
vature of the gastric body.
Figure 3. (A) A low-power histological picture of the gastric MALT lymphoma lesion
resected at the first operation on 21 November 1995 showing distinct, poorly circum-
scribed lymphoid follicles and the infiltration of lymphoma cells into the muscularis pro-
pria of the gastric wall. The lesions were covered with normal mucosa (H＆E stain). (B)
High-power view showing the diffuse proliferation of many small centrocyte-like cells (H
＆E stain). (C) The histopathological diagnosis of the rectal submucosal tumors focally
resected on 10 June 1999 was MALT lymphoma which was similar to the gastric lesion
which had been resected on 21 November 1995. (D) A low-power histological picture of
the rectal MALT lymphoma lesion focally resected on 10 June 1999 showing distinct,
poorly circumscribed lymphoid follicles and the infiltration of lymphoma cells into the
muscularis propria of the gastric wall. The lesions were covered with normal mucosa (H
＆E stain).[page 78] [Rare Tumors 2011; 3:e24]
ic B-cells and into the follicles; iii) tumor cells
likely to be differentiated into the plasma cells
(lymphoplasmacytoid  cells);  iv)  lympho-
epithelial  lesions  (LEL)  and  so  on.13-15
Centrocyte-like  cells,  diffuse  proliferation  in
the  marginal  zone  of  monocytic  B-cell  lym-
phoma cells, LEL, positive IgG-reconstruction
and monoclonal proliferation were observed in
the current case. In addition, the histopatho-
logical  examinations  revealed  positive
immunoreactivity for CD20 (L26) and CD79a
and negative immunoreactivity for cyclin D1
and CD5. Therefore, with the case herein pre-
sented many of the above-mentioned features
of MALT lymphoma. The surgical specimen in
the last (third) focal resection showed that the
tumor cells appeared to be well differentiated
plasma cells, partly because a lymphoma cell
characterized as a MALT lymphoma may devel-
op  and  proliferate  monoclonally  over  an
extended time through metachronous develop-
ment. Since many of metachronous and multi-
ple MALT lymphoma cases can arise from iden-
tical cells, the MALT lymphoma which devel-
oped metachronously in the gastric and rectal
lesions may have arisen from identical lym-
phoma cells and was more likely to be differen-
tiated into plasma cells.
MALT  lymphoma  is  likely  to  develop  from
inflammatory  lesions  after  a  prior  infection,
not only an H. pylori infection of the stomach,
but  also  autoimmune  diseases,  such  as,
Torsten Sjogren’s syndrome of salivary gland
and  thymus  and  Hashimoto’s  disease
(hypothyroidism) of thyroid have been associ-
ated  with  the  development  of  MALT  lym-
phoma.2 While MALT lymphomas in the gas-
trointestinal  tract  are  likely  to  develop  from
gastric lesions associated with H. pylori infec-
tion;  MALT  lymphoma  development  in  the
colon and rectum in which H. pylori infection
and other apparent inflammation are not seen,
is comparatively rare. Patients with MALT lym-
phoma  have  a  higher  incidence  of  colonic
involvement than previously reported.
Furthermore,  Yoshino  et  al.16 and
Thieblemont et al.17 reported that synchronous
and multiple MALT lymphoma cases occur in 7
(2.3%) of 304 (Yoshino et al.), 54 (35.1%) of
154  (Thieblemont  et  al.)  MALT  lymphoma
cases, respectively. These incidences are dif-
ferent, but low in general. Metachronous MALT
lymphoma  cases  (including  the  cases  with
metachronous  development  of  MALT  lym-
phoma  and  other  lymphoma  types)  are  very
rare.  A  literature  search  of  Japana  Centra
Revuo  Medicina  identified  only  3  cases7-9 of
metachronous MALT lymphomas (Key words:
MALT lymphoma, metachronous, case reports
excluding the minutes of oral presentations,
retrieval period: 1983-2008) and a search of
MEDLINE found only 4 cases3-6 of metachro-
nous MALT lymphomas (Key words: MALT lym-
phoma, metachronous). No cases of MALT lym-
phomas  that  develop  metachronously  and
ectopically in gastric and rectal lesions have
been reported and this present case seems to
be the first reported to date.
There  are  various  macroscopic  forms  of
MALT  lymphoma.  Most  gastric  MALT  lym-
phoma  show  surface-accretive  lesions  with
groveling progress in the mucosa because the
mucosal invasive type accounts for many of the
gastric  MALT  lymphoma  cases.  In  contrast,
because colonic MALT lymphomas are likely to
progress  mainly  in  the  submucosal  layers,
most colonic MALT lymphomas appear to be a
macroscopic  form  of  submucosal  tumor
(SMT).18,19 In  the  present  case,  the  gastric
lesion showed swollen and reddish folds on the
greater  curvature  and  the  colonic  lesion
showed  a  flat  elevation  like  a  SMT.  These
macroscopic  forms  were  characteristic  of
MALT lymphoma as described above. 
MALT lymphomas also show characteristic
chromosomal and genetic features. Most MALT
lymphomas  have  API2/MALT1  chimeric  DNA
resulting from a translocation of t(11;18).20,21
These chromosomal changes are recognized in
about 50% of all MALT lymphomas and in 10-
20%  of  all  gastric  MALT  lymphomas.22
Additional chromosomal changes include tri-
somy 323 and t(1;14) with a translocation of the
Bcl10-gene.24 Many  of  the  MALT  lymphoma
cases  with  the  t(11;18)  translocation  are
resistant to eradication of H. pylori and show
multiorgan involvement,25,26 although, there is
little or no concern of their developing malig-
nant  potential.  However,  several  previous
reports indicate that, in most MALT lymphoma
patients with multiple organ involvement, the
multiple  lesions  consisted  of  an  identical
clone.27-29 Iwano et al. reported that most API2-
MALT1-positive gastric MALT lymphomas with
multiple lesions or multiple organ involvement
appear to originate from a single lesion and
disseminate to other lesions or organs.30 In the
present case, the presence of t(11;18), API2-
MALT1 fusion transcripts and the monoclonal-
ity of CDR3 was not determined, partly because
there  was  no  frozen  sample  of  the  tumor
lesions. Therefore, it is impossible to deter-
mine whether the primary lesion metastasized
to the rectum or whether the MALT lymphomas
developed  metachronously  from  the  back-
ground so common in the gastric and rectal
lesions. In the current case, the rectal MALT
lymphoma developed about 3 and a half years
after the operation for the gastric lesion. The
incidence of metastasis from a gastric lesion
to the rectum is very low, with respect to the
metastatic  pathway.  The  background  factors
common to gastric and rectal lesions are not
known  nor  is  the  association  between  the
infection and the inflammation caused from
the infection or other factors. However, anec-
dotal  reports  have  indicated  that  antibiotics
were effective for treating colonic MALT lym-
phoma  regardless  of  the  presence  of  an  H.
pylori infection  in  the  gastric  lesion.18,19,31
These  reports  suggested  the  possibility  of  a
correlation between colonic MALT lymphoma
development and colonic bacteria.
In contrast, Grünberger et al. reported that
16 patients with extra-gastric MALT lymphoma
and positive H. pylori infection in the gastric
lesion underwent eradication before the initi-
ation of definitive treatment with extra-gastric
MALT lymphoma and none of these 16 patients
showed  regression  of  the  lymphoma.32 This
Case Report
Figure 4. (A)(B) Colonoscopic findings on 13 May 1999, about 3 and a half years after
the first operation for gastric MALT lymphoma, showed two SMT-like lesions in the rec-
tum. The biopsy specimens indicated that the lesions were suspected to be malignant
lymphomas.[Rare Tumors 2011; 3:e24] [page 79]
report suggested that H. pylori-eradication or
antibiotic  treatment  targeting  H.  pylori was
ineffective for treatment of extra-gastric MALT
lymphomas.32
In the past, the first line of therapy for the
limited type of malignant lymphoma has been
a resection of the tumor including the gastric
lesion.  Adjuvant  chemotherapy  has  been
administered in Japan and adjuvant radiother-
apy  in  Western  countries  and  the  United
States  for  cases  with  positive  lymph  node
metastasis and focal progression. The concept
of  MALT  lymphoma  was  introduced  in  the
1980s1,13 and  the  correlation  with  H.  pylori
infections was initially suggested in 1995.33-
35 Eradication of H. pyloriis now considered to
be an internationally accepted standard thera-
py for the limited type of gastric MALT lym-
phoma. In particular, in those cases with posi-
tive  H.  pylori infections,  eradication  of  the
infection has been shown to improve the cure
rate from 80% to 90%. Even if the patients are
negative for H. pylori infections, eradication is
advantageous in the cases positive for H. heil-
mani or false-negative for H. pylori infections,
however,  most  cases  negative  for  H.  pylori
infections  have  the  API2/MALT1  transcripts
produced  by  the  translocation  of  t(11;18),22
reveal multiorgan involvements and show no
effect of H. pylori eradication. 
A salvage operation is the standard therapy
for patients who do not respond to eradication,
however, radiation therapy,36,37 administration
of CHOP therapy,38 single drug therapy with
cyclophosphamide,39  cladribine,40 etc.  and
Rituximab (anti-CD20 antibody)41-43 are other
selected forms of treatment.
No therapy has been established for colonic
MALT  lymphoma.  Anecdotal  reports  have
described  effective  eradication  for  colonic
MALT  lymphoma  as  with  gastric  lesions,
regardless of H. pylori infection status in the
stomach,19,31,44,45 and it would seem appropriate
to  perform  eradication  therapy  because  it
involves  simple  oral  therapy  for  7  days.
However, it has been reported that eradication
therapy  was  not  effective  for  extra-gastric
MALT lymphoma in one study32 and there are a
number of questions of its therapeutic effect.
Surgical resection is the most frequent thera-
peutic procedure for rectal MALT lymphoma in
Japan. Further more, CHOP therapy and oral
cyclophosphamide,39 etc., or Rituximab etc. are
used as they are with gastric MALT lymphoma.
In  the  present  case,  eradication  seems
appropriate to the initially selected therapeutic
procedure, because the patient was positive for
H. pylori infection. Ho wever, in 1995, when
the correlations between MALT lymphoma and
H.  pylori were  initially  reported,  the  patient
and her family strongly requested a surgical
resection. Therefore, a total gastrectomy was
performed. The pathological examination sug-
gested the involvement of the regional lymph
nodes and the invasion into the spleen, thus
two courses of CHOP therapy were added as
adjuvant chemotherapy, however, rectal MALT
lymphomas  thereafter  developed  metachro-
nously and repeatedly. Anecdotal reports on the
effectiveness of eradication for colonic MALT
lymphomas  have  been  published19,31,44,45 and
eradication therapy could have been adminis-
tered, however, because the patient and her
family  requested  a  surgical  operation,  we
judged that the advantages due to a preserva-
tion of a quality of life by not performing a
colostomy were therefore greater than the dis-
advantages due to a relapse after a focal resec-
tion and thus selected a trans-anal focal resec-
tion of the tumor. It was strongly suggested
that MALT lymphomas are likely to develop due
to  some  background  factor  common  in  the
stomach and rectum. 
These common factors in the stomach and
rectum are unknown, however, because sever-
al cases in which antibiotics for eradication
were  effective,  have  been  reported  to
date,19,31,44,45such factors may be an infection of
some kind other than H. pylori.
Eradication  therapy  was  administered  in
August 2006, to prevent further metachronous
developmentof MALT lymphoma. In the current
case, careful observations, including periodical
endoscopic examinations, computed tomogra-
phy (CT) scans, measurement of the levels of
serum  interleukin-2  (s-IL-2)  receptor,  are
needed.  Further  experimental  and  clinical
research on the most appropriate treatments
for  colonic  MALT  lymphoma  is  awaited  with
great interest.
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